IP Verse

Solid Forms Of A Selective Cdk4/6 Inhibitor - EP3431475

The patent EP3431475 was granted to Pfizer on Apr 7, 2021. The application was originally filed on Feb 8, 2014 under application number EP18186675A. The patent is currently recorded with a legal status of "Revoked".

EP3431475

PFIZER
Application Number
EP18186675A
Filing Date
Feb 8, 2014
Status
Revoked
Jul 10, 2025
Publication Date
Apr 7, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GALENICUM HEALTH SLUJan 7, 2022GALENICUM HEALTH SLUADMISSIBLE
GENERICS UKJan 7, 2022ELKINGTON AND FIFEADMISSIBLE
TEVA PHARMACEUTICALSJan 6, 2022D YOUNGADMISSIBLE
STADA ARZNEIMITTELJan 3, 2022HAMM & WITTKOPPADMISSIBLE

Patent Citations (23) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS6106864
DESCRIPTIONUS6936612
DESCRIPTIONUS7208489
DESCRIPTIONUS7345171
DESCRIPTIONUS7456168
DESCRIPTIONUS7781583
DESCRIPTIONUS7863278
DESCRIPTIONWO0035298
DESCRIPTIONWO03062236
DESCRIPTIONWO2005005426
DESCRIPTIONWO2008032157
DESCRIPTIONWO9111172
DESCRIPTIONWO9402518
DESCRIPTIONWO9855148
OPPOSITIONEP2958916
OPPOSITIONUS7345171
OPPOSITIONUS7781583
OPPOSITIONWO2005005426
OPPOSITIONWO2008032157
OPPOSITIONWO2011088806
OPPOSITIONWO2016024249
SEARCHUS7781583
SEARCHWO2005005426

Non-Patent Literature (NPL) Citations (48) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- CHEN et al., J. Pharmaceutical and Biomedical Analysis, (20010000), vol. 26, page 63
DESCRIPTION- FINNIN; MORGAN, J Pharm Sci, (19990000), vol. 88, no. 10, pages 955 - 958
DESCRIPTION- H. LIEBERMAN; L. LACHMAN, Pharmaceutical Dosage Forms: Tablets, (19800000), vol. 1
DESCRIPTION- J. Am. Chem. Soc., (19380000), vol. 60, page 309
DESCRIPTION- LIANG; CHEN, Expert Opinion in Therapeutic Patents, (20010000), vol. 11, no. 6, pages 981 - 986
DESCRIPTION- VERMA et al., Pharmaceutical Technology On-line, (20010000), vol. 25, no. 2, pages 1 - 14
OPPOSITION- Anonymous, "A basic guide to particle characterization", Malvern Instruments Limited, (20140000), pages 1 - 23, XP055657885
OPPOSITION- Anonymous, "A Study In Healthy Volunteers To Estimate The Effect Of The Active Ingredient Particle Size And Percentage Of The Excipients Used To Formulate The Capsules In The Dissolution Rate Of The Formulations In The Gastrointestinal Tract", NCT01844323, pages 1 - 6, URL: https://clinicaltrialls.gov/ct2/show/NCT01844323, XP055614966
OPPOSITION- Anonymous, "Characterization of crystalline and partially crystalline solids by X-ray powder diffraction (XRPD", US PHARMACOPOEIA, (20130000), pages 1 - 5, XP055621956
OPPOSITION- Anonymous, "COSMOthermX User Guide version c30 1701", COSMOthermX User Guide, (20130000), pages 1 - 19, XP055902239
OPPOSITION- Anonymous, "Determination of the specific surface area of solids by gas adsorption - BET method", International Standard ISO, Geneva Switzerland, (20100000), vol. 9277, pages 1 - 30, XP003035663
OPPOSITION- "Chapter 10 - Reactive Crystallization", Hsien-Hsin Tung, Edward L. Paul, Et Al., Crystallization of Organic Compounds, An Industrial Perspective, (20090101), pages 207 - 233, XP055613394
OPPOSITION- "Chapter 6 - Gravimetric Analysis", Gary D. Christian, ANALYTICAL CHEMISTRY, 4th ed., (19860101), pages 150 - 173, XP055613392
OPPOSITION- "Chapter 8 - Gravimetric Methods of Analysis", David Harvey, Modern Analytical Chemistry, (20000000), pages 233 - 247, XP055613397
OPPOSITION- "Chapter 8 - Gravimetric Methods of Analysis", David Harvey, Modern Analytical Chemistry, (20000101), pages 232 - 247, XP055613397
OPPOSITION- Christoph Loschen; Klamt; Andreas, "Solubility prediction, solvate and cocrystal screening as tools for rational crystal engineering", J Pharm Pharmacol., (20150000), vol. 67, pages 803 - 811, XP055521197
OPPOSITION- David Harvey, "Chapter 8 - Gravimetric Methods of Analysis", Modern Analytical Chemistry, (20000101), pages 232 - 247, XP055613397
OPPOSITION- FRY D W; ET AL, "Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts", Molecular Cancer Therapeutics, (20041100), vol. 3, no. 11, pages 1427 - 1437, XP002333887
OPPOSITION- FRY D W,ET AL, "Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.", Molecular Cancer Therapeutics, American Association for Cancer Research, US, US , (20041101), vol. 3, no. 11, ISSN 1535-7163, pages 1427 - 1438, XP002333887
OPPOSITION- Gary D. Christian, "Chapter 6 - Gravimetric Analysis", ANALYTICAL CHEMISTRY, 4th ed., (19860101), pages 150 - 173, XP055613392
OPPOSITION- Gary D Christian, "Gravimetric Analysis", Analytical Chemistry, (19860000), pages 150 - 173, XP055613392
OPPOSITION- H. A. LIEBERMAN, "Pharmaceutical Dosage Forms: Tablets", Pharmaceutical Dosage Forms: Tablets, New York, (19890000), page 12, XP055255581
OPPOSITION- "Handbook of Industrial Crystallization", Allan S Myerson Et Al, Handbook of Industrial Crystallization, second edition, Butterworth-Heinemann, Boston, (20020000), page 246, 249, XP055297329
OPPOSITION- Herbert A . Lieberman Et Al., Pharmaceutical Dosage Forms - Tablets, Marcel Dekker, (19890101), pages 2pp, 5 - 6, XP055255581
OPPOSITION- HILFIKER R, "Solid-state and life cycle management", Polymorphism in the Pharmaceutical Industry, (20060000), page 15, XP055621965
OPPOSITION- Hsien-Hsin Tung, Edward L. Paul, Et Al., "Chapter 10 - Reactive Crystallization", Crystallization of Organic Compounds, An Industrial Perspective, (20090101), pages 207 - 233, XP055613394
OPPOSITION- Hsien-Hsin Tung; Edward L Paul; Et Al, "Reactive Crystallization", Crystallization of Organic Compounds, An Industrial Perspective, (20090000), pages 207 - 233, XP055613394
OPPOSITION- J. SWARBRICK, "Crystallization: Particle Size Control", Encyclopedia of Pharmaceutical Technology Third Edition Volume 1, New York, (20070000), vol. 1, pages 858 - 871, XP055902204
OPPOSITION- KJ. PALUCH et al., "Impact of Alternative solid state forms and specific surface area of high-dose, Hydrophilic Active Pharmaceutical Ingredients on Tabletability", Mol. Pharmaceutics, (20130000), vol. 10, pages 3628 - 3639, XP055902243
OPPOSITION- LIEBERMAN Herbert A., "Preformulation Testing", Pharmaceutical dosage forms: tablets SECOND EDITION, REVISED AND EXPANDED, (19890000), vol. 1, pages 5-6 - 12, XP055577039
OPPOSITION- M. E. AULTON, "Dissolution and Solubility", Pharmaceutics: The science of dosage form design, London, (20020000), pages 15 - 32, XP055618335
OPPOSITION- M. E. AULTON, "Powder Flow", Pharmaceutics: The science of dosage form design, London, (20070000), pages 168 - 171, XP055684119
OPPOSITION- Merkus Henk G., "Errors in particle size and concentration analysis of pharmaceuticals", Pharmaceutical Development and Technology, (20191101), vol. 25, no. 2, pages 252 - 259, XP055880922
OPPOSITION- Pfizer, "NCT01602887", ClinicalTrials.gov, (20121212), pages 1 - 3, ClinicalTrials.gov, URL: https://clinicaltrials.gov/ct2/show/NCT01602887?term=NCT01602887&draw=2&rank=1, (20220119), XP055880935
OPPOSITION- P. L. TOOGOOD et al., "Specific inhibition of cyclin-dependent kinase 416 by PD 0332991 and associated antitumor activity in human tumor xenografts", Mol Cancer Ther, (20040000), vol. 3, pages 1427 - 1437
OPPOSITION- Richard D. Braatz, Mitsuko Fujiwara, Thomas J. Wubben, Effendi Rusli, "Crystallization: Particle Size Control", Richard D. Braatz, Mitsuko Fujiwara, Thomas J. Wubben, Effendi Rusli, James Swarbrick, Encyclopedia of PHARMACEUTICAL TECHNOLOGY Third Edition VOLUME 1 , Informa Healthcare USA, Inc., (20070101), pages 858 - 871, XP055901819
OPPOSITION- Sharma P. K., "35 Design of filtration and drying operations", Chemical Engineering in the Pharmaceutical Industry: Active Pharmaceutical Ingredients, 2nd Edition, pages 799 - 831, XP055902265
OPPOSITION- Sharma Praveen K, Murugesan Saravanababu, Tabora Jose E, "Chapter 35 DESIGN OF FILTRATION AND DRYING OPERATIONS", Sharma Praveen K, Murugesan Saravanababu, Tabora Jose E, David J. am Ende and Mary T. am Ende, Chemical Engineering in the Pharmaceutical Industry: Active Pharmaceutical Ingredients, Second Edition., John Wiley & Sons, Inc, (20190101), pages 799 - 831, XP055901811
OPPOSITION- Ulery A. L., Et Al., "X-ray diffraction", Methods of Soil Analysis: Mineralogical methods, (20080000), page 97, XP055902380
OPPOSITION- X. M. ZENG et al., "Particle interactions in dry powder formulations for inhalation", Department of Pharmacy, London and New York, pages 1 - 47, XP055901877
OPPOSITION- MORISSETTE SHERRY L; ALMARSSON \RN; PETERSON MATTHEW L; REMENAR JULIUS F; READ MICHAEL J; LEMMO ANTHONY V; ELLIS STEVE; CIMA MICHAEL J; GARDNER COLIN R, "High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids", Advanced Drug Delivery Reviews, (20040000), vol. 56, no. 3, pages 275 - 300, XP009072233
OPPOSITION- B. Y. SHEKUNOV et al., "Crystallization processes in pharmaceutical technology and drug delivery design", Journal of Crystal Growth, (20000000), vol. 211, doi:10.1016/S0022-0248(99)00819-2, pages 122 - 136, XP004193361
OPPOSITION- B. P. CHEKAT et al., "Palbociclib Commercial Manufacturing Process Development. Part III. Deprotection Followed by Crystallization for API Particle Property Control", Org Proc Res Dev, (20160000), vol. 20, no. 121, pages 1227 - 1226, XP055376350
OPPOSITION- A. S. MYERSON et al., "Pharmaceutical Crystallization", Crystal Growth & Des, (20110000), vol. 11, no. 4, pages 887 - 895, XP055318791
OPPOSITION- Soojin Kim; Bruce Lotz; Mark Lindrud; Kevin Girard; Terence Moore; Karthi Nagarajan; Mario Alvarez; Tu Lee; Faranak Nikfar; Martha Davidovich; Sushil Srivastava; San Kiang, "Control of the Particle Properties of a Drug Substance by Crystallization Engineering and the Effect on Drug Product Formulation", Organic Process Research & Development, (20050000), vol. 9, no. 6, pages 894 - 901, XP055613400
OPPOSITION- Soojin Kim, Bruce Lotz, Mark Lindrud, Kevin Girard, Terence Moore, Karthi Nagarajan, Mario Alvarez, Tu Lee, Faranak Nikfar, Martha Davidovich, Sushil Srivastava, San Kiang, "Control of the Particle Properties of a Drug Substance by Crystallization Engineering and the Effect on Drug Product Formulation", Organic Process Research & Development, American Chemical Society, US, US , (20051101), vol. 9, no. 6, doi:10.1021/op050091q, ISSN 1083-6160, pages 894 - 901, XP055613400
OPPOSITION- D. PRAT et al., "Sanofi's Solvent Selection Guide: A Step Toward More Sustainable Processes", Org Proc Res Dev, (20130000), vol. 17, doi:10.1021/op4002565, pages 1517 - 1525, XP055614972
OPPOSITION- S BYRN et al., "Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations", Pharmaceutical Research, (19950700), vol. 12, no. 7, doi:10.1023/A:1016241927429, pages 945 - 954, XP055399407

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents